Sex differences in minocycline-induced neuroprotection after experimental stroke.
Minocycline is neuroprotective in clinical and experimental stroke studies, due in part to its ability to inhibit poly (ADP-ribose) polymerase. Previous preclinical data have shown that interference with poly (ADP-ribose) polymerase signaling leads to sex-specific neuroprotection, reducing stroke injury only in males. In this study, we show that minocycline is ineffective at reducing ischemic damage in females after middle cerebral artery occlusion, likely due to effects on poly (ADP-ribose) polymerase signaling. Clinical trials must consider possible sex differences in the response to neuroprotective agents, if we hope to translate promising therapies to stroke patients of both sexes.
Li
Jun
J
Department of Neurology, University of Connecticut Health Center, Farmington, Connecticut 06030, USA.
McCullough
Louise D
LD
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D005260:Female; D020244:Infarction, Middle Cerebral Artery; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008911:Minocycline / Q000494:pharmacology*; D018696:Neuroprotective Agents / Q000494:pharmacology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D012737:Sex Factors; D020521:Stroke / Q000188:drug therapy*; D017211:Treatment Failure
D018696:Neuroprotective Agents; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D008911:Minocycline